The most popular drugs used to prevent osteoporosis that causes low mineral density and weakened microstructure of bones are bisphosphonates. Bisphosphonates can be administered in several ways, but each delivery method has drawbacks. Due to this, new methods of their delivery are being sought. Titanium implants coated with calcium titanate were prepared in this work as carriers for bisphosphonates. Such a modification has been proposed in order to improve the therapeutic properties of the implant. Slow release of the drug at a constant level will positively affect the recovery process and osteointegration. Furthermore, the drug will be slowly released very close to the area affected by osteoporosis. These studies were confirmed, using a variety of methods: EDS and XPS (to examine surface modification and drug sorption), Raman mapping (to proof the presence of the drug on the entire surface of the material) and UV-VIS spectroscopy (to determine bisphosphonate sorption and release profile). It was proved that the active substance (sorbed on the implant) could be completely released upon contact with body fluids within a month. The obtained results will allow for the production of endoprostheses dedicated to patients with osteoporosis in the future.
Keywords: bisphosphonates; calcium titanate; controlled release; drug carriers; osteoporosis.
© 2021 Wiley Periodicals LLC.